Enanta Pharma (ENTA) Tops Q2 EPS by 10c, Misses on Revenue
Tweet
Share
E-mailGet Alerts ENTA Hot Sheet
Join SI Premium – FREE
Enanta Pharma (NASDAQ: ENTA) reported Q2 EPS of ($1.06), $0.10 better than the analyst estimate of ($1.16). Revenue for the quarter came in at $14.9 million versus the consensus estimate of $15.95 million.
For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Movano (MOVE) Misses Q2 EPS by 195c
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- SVB & T Corporation (SVBT) Tops Q2 EPS by 275c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
